| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 03 Nov 2026 |
Form 4: Enguent Jean-Pierre, Vice President, R&DSS
Received 35,000 shares by exercise or conversion ($350) · Granted 50,000 Employee Stock Option Plan (right to buy) · Sold 35,000 shares ($48.3K) |
| 28 Oct 2026 | REPORT OF FOREIGN PRIVATE ISSUER |
| 27 Oct 2026 | REPORT OF FOREIGN PRIVATE ISSUER |
| 16 Oct 2026 | REPORT OF FOREIGN PRIVATE ISSUER |
| 16 Oct 2026 | REPORT OF FOREIGN PRIVATE ISSUER |
| 14 Oct 2026 | FORM 425 |
| 14 Oct 2026 | REPORT OF FOREIGN PRIVATE ISSUER |
| 07 Oct 2026 |
Form 4: Enguent Jean-Pierre, Vice President, R&DSS
Received 35,000 shares by exercise or conversion ($350) · Granted 50,000 Employee Stock Option Plan (right to buy) · Sold 35,000 shares ($85.9K) |
| 06 Oct 2026 |
Form 4: Ward Peter, Director
Granted 8,268 Employee Stock Option Plan (right to buy) |
| 06 Oct 2026 |
Form 4: Fergusson David Alexander, Director
Granted 17,487 Employee Stock Option Plan (right to buy) |
| 06 Oct 2026 |
Form 4: Pellaton Eric Adrien, Director
Granted 24,810 Employee Stock Option Plan (right to buy) |
| 02 Oct 2026 | REPORT OF FOREIGN PRIVATE ISSUER |
| 25 Sep 2026 | REPORT OF FOREIGN PRIVATE ISSUER |
| 25 Sep 2026 | REPORT OF FOREIGN PRIVATE ISSUER |
| 14 Sep 2026 | REPORT OF FOREIGN PRIVATE ISSUER |
| 11 Sep 2026 | REPORT OF FOREIGN PRIVATE ISSUER |
| 03 Sep 2026 |
Form 4: Enguent Jean-Pierre, Vice President, R&DSS
Received 15,000 shares by exercise or conversion ($150) · Sold 15,000 shares ($36K) |
| 26 Aug 2026 | REPORT OF FOREIGN PRIVATE ISSUER |
| 26 Aug 2026 |
Form 3: Hirsch Alexander Sebastian, Chief Marketing Officer
No securities owned |
Loading...